4//SEC Filing
Rai Sukhwinder Singh 4
Accession 0001516551-22-000045
CIK 0001516551other
Filed
Nov 14, 7:00 PM ET
Accepted
Nov 15, 12:24 PM ET
Size
16.6 KB
Accession
0001516551-22-000045
Insider Transaction Report
Form 4
Rai Sukhwinder Singh
Director
Transactions
- Award
Common Stock
2022-11-10+22,157→ 22,157 total(indirect: By Trust) - Award
Stock Option (Right to Buy)
2022-11-10+390,000→ 390,000 totalExercise: $1.60Exp: 2024-04-02→ Common Stock (390,000 underlying) - Award
Common Stock
2022-11-10+73,561→ 73,561 total(indirect: By Spouse) - Award
Stock Option (Right to Buy)
2022-11-10+146,250→ 146,250 totalExercise: $1.71Exp: 2022-12-22→ Common Stock (146,250 underlying) - Award
Stock Option (Right to Buy)
2022-11-10+146,250→ 146,250 totalExercise: $0.11Exp: 2025-02-06→ Common Stock (146,250 underlying) - Award
Stock Option (Right to Buy)
2022-11-10+195,000→ 195,000 totalExercise: $0.08Exp: 2025-08-03→ Common Stock (195,000 underlying)
Footnotes (7)
- [F1]The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").
- [F2]The shares are held through the Canaccord Genuity Trust.
- [F3]For each indirect account, Mr. Rai disclaims beneficial ownership except to the extent of his pecuniary interest, if any.
- [F4]The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.
- [F5]The options underlying this award are fully vested.
- [F6]The options vest, or have vested, in equal installments on each of February 6, 2020, February 6, 2021, February 6, 2022, February 6, 2023.
- [F7]8.33% of the options vested on the grant date of August 3, 2020. 8.33% of the options vest, or have vested, on each monthly anniversary of the grant date.
Documents
Issuer
Skye Bioscience, Inc.
CIK 0001516551
Entity typeother
Related Parties
1- filerCIK 0001947352
Filing Metadata
- Form type
- 4
- Filed
- Nov 14, 7:00 PM ET
- Accepted
- Nov 15, 12:24 PM ET
- Size
- 16.6 KB